DelveInsight's latest Gastroesophageal Reflux Disease Market Insights report provides a comprehensive assessment of the GERD treatment landscape, including current treatment practices, emerging therapies, market share, epidemiology, key market drivers, and market forecasts across the United States, EU4, the United Kingdom, and Japan.

The gastroesophageal reflux disease market continues to face challenges due to a limited number of approved treatment options and persistent unmet needs, particularly among patients who do not achieve adequate symptom control with proton pump inhibitors (PPIs). However, advances in diagnosis and the development of next-generation therapies, including BLI5100 (Tegoprazan) from Braintree Laboratories and Linaprazan glurate from Cinclus Pharma, are expected to support market growth during the forecast period.

Gastroesophageal Reflux Disease Market Key Highlights

  • The United States GERD market was valued at approximately USD 3.3 billion in 2024.
  • The US recorded approximately 33 million diagnosed prevalent GERD cases in 2024, highlighting the substantial clinical burden of the disease.
  • VOQUEZNA (vonoprazan) established an early position as the first P-CAB approved for GERD in the United States and is projected to expand its market presence over the next decade.
  • BLI5100 (Tegoprazan) and Linaprazan glurate are among the key emerging therapies being evaluated for GERD.
  • NERD represented the majority of GERD cases in the US in 2024, accounting for approximately 23 million cases, while erosive esophagitis accounted for approximately 10 million cases.
  • The US GERD market is projected to grow at a CAGR of approximately 6% during 2025–2034.
  • Key companies involved in the GERD treatment landscape include Braintree Laboratories, Cinclus Pharma, Phathom Pharmaceuticals, Takeda, and others.

Discover more about the GERD market size, forecast, and patient population:
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Factors Driving the Growth of the Gastroesophageal Reflux Disease Market

Rising GERD Prevalence

According to DelveInsight's estimates, approximately 33 million diagnosed prevalent cases of GERD were recorded in the United States in 2024. The substantial patient population, combined with ongoing diagnosis and disease-awareness efforts, is expected to support continued demand for GERD therapies.

Growing Adoption of VOQUEZNA

VOQUEZNA (vonoprazan), developed by Phathom Pharmaceuticals, is the first P-CAB approved for GERD in the US. According to the supplied market assessment, its rapid onset and consistent acid suppression may support its use among patients with high acid burden, persistent nocturnal symptoms, or inadequate control during PPI tapering.

Emergence of Next-Generation Therapies

The GERD pipeline is evolving with the development of next-generation P-CABs, including BLI5100 (Tegoprazan) from Braintree Laboratories and Linaprazan glurate from Cinclus Pharma. These candidates are expected to expand treatment options for patients who remain inadequately controlled on conventional PPI therapy.

Increasing Interest in P-CABs

Potassium-competitive acid blockers represent an emerging treatment approach in acid-related gastrointestinal disorders. Their ability to provide rapid and sustained gastric acid suppression has increased interest in this therapeutic class as an alternative or complement to traditional PPIs.

Gastroesophageal Reflux Disease Market Analysis

GERD management continues to be dominated by generic PPIs and H2-receptor antagonists (H2RAs), supported by long-standing physician familiarity and widespread availability.

Despite their widespread use, PPIs may have limitations, including delayed onset of action, variable acid suppression, insufficient nocturnal control, and reduced healing efficacy in some patients with moderate-to-severe erosive esophagitis.

VOQUEZNA (vonoprazan) has emerged as an important addition to the US GERD treatment landscape. As a P-CAB, it provides a different mechanism of acid suppression compared with conventional PPIs and has demonstrated faster and more consistent acid control.

Meanwhile, BLI5100 (Tegoprazan) from Braintree Laboratories and Linaprazan glurate from Cinclus Pharma are advancing through late-stage development. Their potential entry into the market could increase competition within the P-CAB segment and provide additional treatment options for patients who remain inadequately controlled with standard therapy.

Gastroesophageal Reflux Disease Competitive Landscape

The GERD competitive landscape includes marketed therapies as well as emerging candidates designed to improve acid suppression and address persistent treatment gaps.

Braintree Laboratories' BLI5100 (Tegoprazan)

BLI5100 (Tegoprazan) is a next-generation P-CAB being developed for acid-related gastrointestinal disorders. The orally administered therapy is designed to provide rapid and durable gastric acid suppression by directly targeting the proton pump in gastric parietal cells.

According to the supplied information, BLI5100 is currently being evaluated in two Phase III clinical studies in the United States for erosive esophagitis and non-erosive reflux disease (NERD).

If approved, BLI5100 could provide another P-CAB option in the US GERD market and compete with existing therapies in patients seeking effective and sustained acid suppression.

Cinclus Pharma's Linaprazan Glurate

Linaprazan glurate is an investigational next-generation P-CAB and a prodrug of linaprazan. It is being developed with the goal of providing rapid and sustained gastric acid suppression.

The therapy is being investigated for patients with moderate-to-severe erosive GERD and is also being evaluated in combination treatment approaches for Helicobacter pylori infection.

The anticipated entry of these emerging therapies could increase competition in the GERD market and potentially broaden treatment choices for patients who do not achieve adequate control with existing therapies.

Discover more about the latest GERD drugs and emerging therapies @ Gastroesophageal Reflux Disease Drugs Market

Recent Developments in the Gastroesophageal Reflux Disease Market

  • In October 2025: Cinclus Pharma Holding reported favorable guidance from the US FDA following a Chemistry, Manufacturing, and Controls (CMC) meeting regarding the continued development of linaprazan glurate.
  • In October 2025: Phathom Pharmaceuticals announced that additional analyses from the pivotal Phase III pHalcon-NERD-301 trial evaluating VOQUEZNA (vonoprazan) tablets in patients with NERD had been published in the American Journal of Gastroenterology.
  • In August 2025: Braintree Laboratories, a subsidiary of Sebela Pharmaceuticals, reported positive topline results from the 24-week maintenance phase of the pivotal Phase III TRIUMpH study evaluating tegoprazan for GERD.

What is Gastroesophageal Reflux Disease?

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder in which stomach contents, including acid and sometimes bile, flow back into the esophagus. This process, known as acid reflux, can occur when the lower esophageal sphincter does not function properly.

Repeated exposure of the esophagus to gastric contents can cause irritation and inflammation. Common symptoms include heartburn, acid regurgitation, chest discomfort, difficulty swallowing, and chronic cough.

If inadequately managed, GERD may be associated with complications such as esophagitis, esophageal strictures, Barrett's esophagus, and an increased risk of esophageal cancer.

Gastroesophageal Reflux Disease Epidemiology

The GERD epidemiology analysis provides insights into the historical and forecasted patient population across the major markets covered in the report.

In 2024, the United States recorded approximately 33 million diagnosed prevalent GERD cases. NERD represented the majority of cases, with approximately 23 million cases, while erosive esophagitis accounted for approximately 10 million cases.

The report provides epidemiological analysis for the period 2020–2034, segmented by:

  • Prevalent cases of GERD
  • Diagnosed prevalent cases of GERD
  • Gender-specific cases of GERD
  • Age-specific cases of GERD
  • Type-specific cases of GERD
  • Grade-specific cases of GERD
  • Total treated cases of GERD

Gastroesophageal Reflux Disease Market Report Metrics

  • Study Period: 2020–2034
  • Coverage: 7MM
  • Key Companies: Braintree Laboratories (Sebela Pharmaceuticals), Cinclus Pharma, Phathom Pharmaceuticals, Takeda, and others
  • Key Therapies: BLI5100 (tegoprazan), linaprazan glurate, VOQUEZNA (vonoprazan), and other emerging therapies
  • Market Landscape: GERD treatment remains largely dominated by PPIs and H2RAs, while newer potassium-competitive acid blockers (PCABs) are emerging as important treatment options.
  • Emerging Therapies: BLI5100 (tegoprazan) and linaprazan glurate are late-stage PCAB candidates that could expand treatment options for patients inadequately controlled with conventional PPI therapy.
  • VOQUEZNA: Phathom Pharmaceuticals' VOQUEZNA (vonoprazan) is approved in the US for erosive GERD and non-erosive GERD, as well as certain H. pylori treatment regimens.
  • Competitive Outlook: The increasing development of PCAB therapies is expected to intensify competition and provide additional options for patients with persistent or inadequately controlled GERD symptoms.

Scope of the Gastroesophageal Reflux Disease Market Report

The report provides a comprehensive assessment of the GERD market, including:

  • Therapeutic Assessment: Analysis of current marketed and emerging GERD therapies.
  • Market Dynamics: Assessment of key market drivers, barriers, forecast assumptions, and emerging treatment opportunities.
  • Competitive Intelligence: Competitive assessment, SWOT analysis, and market-entry strategies.
  • Unmet Needs: Identification of major treatment gaps across the GERD landscape.
  • KOL and Analyst Insights: Expert perspectives on the evolving treatment landscape.
  • Market Access and Reimbursement: Assessment of reimbursement and market-access considerations across major markets.

Download the report to understand the factors shaping the GERD market over the next decade @ 
Gastroesophageal Reflux Disease Market Forecast

Table of Contents

  1. Key Insights
  2. Report Introduction
  3. Executive Summary of Gastroesophageal Reflux Disease (GERD)
  4. Key Events
  5. Epidemiology and Market Methodology of Gastroesophageal Reflux Disease (GERD)
  6. Gastroesophageal Reflux Disease (GERD) Market Overview at a Glance
  7. Disease Background and Overview of Gastroesophageal Reflux Disease (GERD)
  8. Epidemiology and Patient Population of Gastroesophageal Reflux Disease (GERD)
  9. Patient Journey of Gastroesophageal Reflux Disease (GERD)
  10. Marketed Therapies of Gastroesophageal Reflux Disease (GERD)
  11. Emerging Therapies of Gastroesophageal Reflux Disease (GERD)
  12. Gastroesophageal Reflux Disease (GERD): Seven Major Market Analysis
  13. Unmet Needs of Gastroesophageal Reflux Disease (GERD)
  14. SWOT Analysis of Gastroesophageal Reflux Disease (GERD)
  15. KOL Views of Gastroesophageal Reflux Disease (GERD)
  16. Market Access and Reimbursement
  17. Appendix
  18. DelveInsight Capabilities
  19. Disclaimer
  20. About DelveInsight

Related Reports

Gastroesophageal Reflux Disease Clinical Trial Analysis

The Gastroesophageal Reflux Disease Pipeline Insight – 2026 report provides comprehensive insights into the pipeline landscape, drug profiles, clinical and non-clinical development stages, and key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, and others.

Gastroparesis Market

The Gastroparesis Market Insights, Epidemiology, and Market Forecast – 2036 report provides an in-depth understanding of disease epidemiology, treatment trends, market drivers and barriers, and the competitive landscape, including companies such as Vanda Pharmaceuticals, Processa Pharmaceuticals, Neurogastrx, CinDome Pharma, and others.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive end-to-end solutions to support pharmaceutical and biotechnology companies in strategic decision-making, market assessment, competitive intelligence, and commercial planning.

DelveInsight also provides access to healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.

Contact Us

Kanishk

[email protected]